ReCode Therapeutics

Executive Summary

ReCode Therapeutics is a private genetic medicines company advancing targeted lipid nanoparticle (LNP) delivery systems for mRNA and gene correction therapies, with a focus on respiratory and liver genetic diseases. Founded in 2015 and headquartered in Menlo Park, CA, the company has raised ~$50 million and is currently in Phase 1 development. Its lead programs target primary ciliary dyskinesia (PCD) and cystic fibrosis (CF), leveraging proprietary LNP technology to enable precise delivery to lung and liver tissues. The company's platform holds potential to address significant unmet needs in monogenic respiratory disorders by enabling effective mRNA replacement or gene editing. With initial Phase 1 data expected in the near term, ReCode represents an early-stage opportunity in the nucleic acid therapeutics space, though clinical validation remains pending.

Upcoming Catalysts (preview)

• Q2 2026Initial Phase 1 data for lead PCD candidate40% success
• Q3 2026Phase 1 initiation for CF program60% success
• Q4 2026Strategic partnership or Series B funding round50% success